Rôle des sphingolipides dans la pathogenèse de l'asthme

Chercheurs boursiers - Junior 1 | Concours 2012-2013


David Marsolais

Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec

 

Domaine : Santé circulatoire et respiratoire

Asthma affects up to three hundred thousand Canadians. In spite of significant advances in the field of symptom management, a proportion of asthmatics are refractory to current interventions and no cure is available for this lifelong disease. A class of molecules (sphingolipids) have recently emerged as important modulators of immunity, with therapeutic potential demonstrated in clinical trials for immune-related diseases like multiple sclerosis. Recently, synthetic analogs of these molecules were shown to prevent the development of experimental asthma. This new class of drugs affects the function of many actors involved in asthma pathogenesis. As a consequence, we currently ignore exactly how these new modulators act to alleviate experimental asthma. This research program is dedicated to further define the beneficial effects and mechanisms of action of these analogs and of their targets. The results of this program will improve our knowledge of novel modulators of asthma and ameliorate our general comprehension of the disease with possibility of rapid application for treatment, since these analogs are currently approved for human use.